CD8A and neoplasm: Specifically, we have demonstrated that hTERT peptide vaccination, in combination with adjuvants and metronomic cyclophosphamide therapy, can generate activated hTERT-specific CD4+/CD8+ T effector responses against this tumour associated antigen in cancer patients with therapy-resistant solid tumours.